Literature DB >> 19389453

Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines.

Sean P McBurney1, Ted M Ross.   

Abstract

Envelope (Env) sequences from human immunodeficiency virus (HIV) strains can vary by 15-20% within a single clade and as much as 35% between clades. Previous AIDS vaccines based upon a single isolate often could not elicit protective immune responses against heterologous viral challenges. In order to address the vast sequence diversity in Env sequences, consensus sequences were constructed for clade B and clade C envelopes and delivered to the mouse lung mucosa on the surface of virus-like particles (VLP). Consensus sequences decrease the genetic difference between the vaccine strain and any given viral isolate. The elicited immune responses were compared to a mixture of VLPs with Envs from primary viral isolates. This polyvalent vaccine approach contains multiple, diverse Envs to increase the breadth of epitopes recognized by the immune response and thereby increase the potential number of primary isolates recognized. Both consensus and polyvalent clade B Env VLP vaccines elicited cell-mediated immune responses that recognized a broader number of clade B Env peptides than a control monovalent Env VLP vaccine in both the systemic and the mucosal immune compartments. All three clade C Env vaccine strategies elicited similar responses to clade C peptides. However, both the consensus B and C Env VLP vaccines were more effective at eliciting cross-reactive cellular immune responses to epitopes in other clades. This is the first study to directly compare the breadth of cell-mediated immune responses elicited by consensus and polyvalent Env vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389453     DOI: 10.1016/j.vaccine.2009.04.032

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  HIV-1 virus-like particles produced by stably transfected Drosophila S2 cells: a desirable vaccine component.

Authors:  Lifei Yang; Yufeng Song; Xiaomin Li; Xiaoxing Huang; Jingjing Liu; Heng Ding; Ping Zhu; Paul Zhou
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

2.  A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Authors:  Christine A Bricault; James M Kovacs; Joseph P Nkolola; Karina Yusim; Elena E Giorgi; Jennifer L Shields; James Perry; Christy L Lavine; Ann Cheung; Katharine Ellingson-Strouss; Cecelia Rademeyer; Glenda E Gray; Carolyn Williamson; Leonidas Stamatatos; Michael S Seaman; Bette T Korber; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

3.  A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection.

Authors:  Brendan M Giles; Corey J Crevar; Donald M Carter; Stephanie J Bissel; Stacey Schultz-Cherry; Clayton A Wiley; Ted M Ross
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

4.  Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells.

Authors:  Zaza M Ndhlovu; Alicja Piechocka-Trocha; Seanna Vine; Ashley McMullen; Kegakilwe C Koofhethile; Phillip J R Goulder; Thumbi Ndung'u; Dan H Barouch; Bruce D Walker
Journal:  J Immunol       Date:  2011-05-16       Impact factor: 5.422

5.  Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine.

Authors:  Sean P McBurney; Gary Landucci; Donald N Forthal; Ted M Ross
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-21       Impact factor: 2.205

6.  Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.

Authors:  Brendan M Giles; Stephanie J Bissel; Dilhari R Dealmeida; Clayton A Wiley; Ted M Ross
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

7.  Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

Authors:  Gabriel I Parra; Karin Bok; Ross Taylor; Joel R Haynes; Stanislav V Sosnovtsev; Charles Richardson; Kim Y Green
Journal:  Vaccine       Date:  2012-03-31       Impact factor: 3.641

8.  A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.

Authors:  Brendan M Giles; Ted M Ross
Journal:  Vaccine       Date:  2011-02-12       Impact factor: 3.641

9.  Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Authors:  Mitchell Tyler; Ebenezer Tumban; Agnieszka Dziduszko; Michelle A Ozbun; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

10.  Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.

Authors:  Hermancia S Eugene; Brooke R Pierce-Paul; Jodi K Cragio; Ted M Ross
Journal:  Virol J       Date:  2013-04-02       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.